ReviewHuman vaccines & immunotherapeutics2018
Development of novel vaccine vectors: Chimpanzee adenoviral vectors.
Review in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 77 citations in OpenAlex.
- Article
- Enhancing the breadth of protection in mice with a multivalent influenza vaccine.Communications biology · 2026Article
- Adenoviral Vectors in Gene Therapy: A Detailed Overview.Iranian biomedical journal · 2026Review
- Participant motivators and perceptions of risks and benefits in adult Phase 2/3 COVID-19 vaccine clinical trials.Human vaccines & immunotherapeutics · 2025Article
- Comprehensive and translational pathobiology of COVID-19 based on cellular and molecular techniques.Practical laboratory medicine · 2025Review
- Year-Long Antibody Response to the EuCorVac-19 SARS-CoV-2 Vaccine in Healthy Filipinos.Vaccines · 2025Article
- A quadrivalent norovirus vaccine based on a chimpanzee adenovirus vector induces potent immunity in mice.Virologica Sinica · 2024Article
- User-Friendly Replication-Competent MAdV-1 Vector System with a Cloning Capacity of 3.3 Kilobases.Viruses · 2024Article
- The Biodistribution of Replication-Defective Simian Adenovirus 1 Vector in a Mouse Model.Viruses · 2024Article
- Article
- Chimpanzee adenovirus-mediated multiple gene therapy for age-related macular degeneration.iScience · 2023Article
- Phylogenetic analysis of prospective M. bovis antigens with the aim of developing candidate vaccines for bovine tuberculosis.Journal, genetic engineering & biotechnology · 2023Article
- Safety and Protective Efficacy of a Candidate Vector-Based Vaccine for Bovine Tuberculosis.Vaccines · 2023Article
- Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases.Signal transduction and targeted therapy · 2023Review
- Developments in Rabies Vaccines: The Path Traversed from Pasteur to the Modern Era of Immunization.Vaccines · 2023Review
- Adenovirus Vaccine Containing Truncated SARS-CoV-2 Spike Protein S1 Subunit Leads to a Specific Immune Response in Mice.Vaccines · 2023Article
- Significance of Preexisting Vector Immunity and Activation of Innate Responses for Adenoviral Vector-Based Therapy.Viruses · 2022Review
- Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines.Annals of medicine · 2022Review
- ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calves.Nature communications · 2022Article
- Engineered Sleeping Beauty Transposon as Efficient System to Optimize Chimp Adenoviral Production.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenoviral vector has been employed as one of the most efficient means against infectious diseases and cancer. It can be genetically modified and armed with foreign antigens to elicit specific antibody responses and T cell responses in hosts as well as engineered to induce apoptosis in cancer cells. The chimpanzee adenovirus-based vector is one kind of novel vaccine carriers whose unique features and non-reactivity to pre-existing human adenovirus neutralizing antibodies makes it an outstanding candidate for vaccine research and development. Here, we review the different strategies for constructing chimpanzee adenoviral vectors and their applications in recent clinical trials and also discuss the oncolytic virotherapy and immunotherapy based on chimpanzee adenoviral vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.